New Tools Developed for Studying
Neurodegenerative Brain DisordersSource: Penn State,
Eberly College of Science News
A simple biophysical model of an axon was used to study the
catastrophic consequences of oxidative stress to neurons. The
result was that the protruding microtubule cytoskeleton
collapsed into a deformed structure resembling a string of
beads. This is the same morphology observed during the
degeneration of actual neurons in the brain as seen in the
center panel [see images at
http://www.science.psu.edu/alert/Weiss3-2006.htm]
Here, degeneration of axons of serotonin-transmitting
neurons is caused by the chemical neurotoxin 2'-NH2-MPTP
(Luellen, B.A., Szapacs, M. E., Materese, C. K. & Andrews,
A. M. (2006) Neuropharmacology 50, 297-308). Serotonin neurons
degenerate in diseases such as Alzheimer's disease and also
contribute to depression and anxiety disorders. Serotonin axons
projecting to the hippocampus in the mouse brain, a region
involved in learning and memory, are visualized as gold
thread-like structures using an immunocytochemical technique
(left panel).
21 March 2006—Penn State researchers have created an
elegantly simple model of an axon--the extension of a neuron
that communicates with other neurons--and have used this model
to reproduce a change in the axon's shape that is
characteristic of neurodegenerative disorders such as
Alzheimer's and Parkinson's diseases. This achievement is the
first of its kind in a highly simplified biophysical model
system.
The model provides a novel avenue for investigating the
specific mechanisms that contribute to complex brain diseases.
It also provides a means of discovering new kinds of drugs for
the treatment of these disorders. The research will be
described in a paper to be published in the 4 April 2006 issue
of the Proceedings of the National Academy of Science.
This model, produced in the laboratory of Paul S. Weiss,
Distinguished Professor of Chemistry and Physics at Penn State,
has the essential features of an axon, including a lipid
membrane that encloses a "cytoskeleton" scaffolding, which
produces the axon's shape. The outer membrane was prepared to
contain a very small amount of dye molecules that are sensitive
to ultraviolet light. Shining light on the artificial axons
initiated a photochemical reaction that produced highly
reactive "free radicals" and triggered a catastrophic
oxidative-stress reaction. The result was that the previously
protruding microtubule cytoskeleton collapsed into a
constricted and deformed structure resembling a string of
beads--the same morphology observed during the degeneration of
actual neurons.
Surprisingly, the model reproduced this highly
characteristic "beading" or "pearling" even though it does not
include proteins that were previously thought to be essential
for causing this kind of axon destruction. "One of the beauties
of a simplified model is that it allows you to ask very simple
questions, which sometimes are difficult to answer in a complex
living system, and sometimes to get surprising answers," Weiss
said. "What makes this model so exciting is that it generates
many more questions than it answers," Weiss said. "It will
allow us to test hypotheses of how damage occurs, and
importantly, how we might prevent it. There is a real
opportunity to come up with novel therapeutic treatments."
"There is tremendous urgency right now to determine which
processes cause the destructive mechanisms that we see in
neurodegenerative diseases," said coauthor and Assistant
Professor of Veterinary and Biomedical Sciences, Anne
Milasincic Andrews. "Our study shows that oxidative stress,
whatever its origin, is capable of causing the cytoskeleton of
this artificial system to collapse in the same way that it does
in diseased or aging brains." One of the future experiments
planned by the team is to induce oxidative stress in the
presence of key proteins thought to be involved in the
underlying causes of the brain pathologies associated with
Alzheimer's and Parkinson's diseases to see whether these
proteins accelerate the damaging effects of oxidative
stress.
The study also revealed many specifics about the process of
axon collapse. For example, the degradation rate is faster when
the lipids comprising the membrane have more multiple bonds
(they are more highly unsaturated). The researchers also added
free-radical scavengers, such as vitamins C, E, and K, to the
model system and found that these vitamins delayed or prevented
the degradation of the cytoskeleton. "These antioxidant
vitamins neutralized the free radicals before they had a chance
to degrade the model axon," Weiss explained.
"Simple models also allow us to build more complicated
hypotheses, which later can be tested in complex living
systems, such as laboratory animals. We plan to build into our
model the different brain chemicals that have been implicated
in neurodegenerative processes to see which are the good and
bad actors--which are the most effective in promoting the
radical attack from the membrane to the interior of the axon
and which are the best at disabling free radicals."
One of the types of neurons that degenerate in diseases such
as Alzheimer's disease and that also contribute to depression
and anxiety disorders are neurons that produce the
neurotransmitter serotonin. Andrews and her colleagues have
made a specific model of serotonin-axon degeneration using a
chemical neurotoxin. Evidence of serotonin axon damage,
including beading and pearling, was published recently by
Andrews and her colleagues in the journal Neuropharmacology.
This study used antibodies to label serotonin axons so that the
degenerative process could be visualized. The researchers
injected mice with the chemical neurotoxin, 2'-NH2-MPTP, that
Andrews discovered and has been studying for nearly two
decades. "This latest study shows conclusively that this toxin
destroys serotonin-transmitting neurons," Andrews said, "and it
currently is one of the best models to destroy this type of
neuron. We clearly observed evidence for axonal collapse into
the beaded structures in the brains of these animals a short
time after we gave them the neurotoxin."
Neurodegenerative disorders typically involve many different
types of neurons that produce different neurotransmitter
chemicals. "Our chemical model of neurodegeneration gives us a
tool to disable just one type of neuron so we can begin to
tease apart how each neurotransmitter system participates in
these complex disorders," Andrews said. "We then can study the
behavioral effects of the degeneration of each system and can
test the effectiveness of potential therapeutics to prevent or
reverse the damaging effects."
Other researchers involved in the paper to be published in
the Proceedings of the National Academy of Science include Anne
E. Counterman, previously an NIH postdoctoral fellow in the
Weiss laboratory and now a researcher at Yale University; and
Terrence G. D'Onofrio, a former graduate student in chemistry
in the Weiss group, who is currently a scientist at the U.S.
Army laboratory at Edgewood. The scientists who worked on the
studies published in Neuropharmacology include Beth A. Luellen,
a former neuroscience graduate student in the Andrews group who
is now a postdoctoral fellow at the Penn State Neuroscience
Institute; Matthew E. Szapacs, a former chemistry graduate
student in the Andrews group who currently is a postdoctoral
fellow at the Vanderbilt University School of Medicine; and
Christopher K. Materese, a former chemistry undergraduate
student researcher in the Andrews group who is now a graduate
student in chemistry at the University of North Carolina at
Chapel Hill.
The research project led by Professor Weiss was funded by
the National Science Foundation. The project led by Professor
Andrews was funded by the National Institute of Mental
Health.
[ B K K ]
CONTACTS: Paul S. Weiss: (+1) 814-865-3693, ,
http://www.nano.psu.edu Anne M. Andrews: (+1) 814-865-2970, ,
http://www.brain.psu.edu Barbara K. Kennedy (PIO): (+1)
814-863-4682,
|